IMUX earnings analysis
What we found in IMUX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The provided 10-Q excerpt does not include the income statement, balance-sheet detail beyond cash and foreign-subsidiary net current assets, cash-flow statement, segment results, or MD&A operating trends; therefore revenue, margins, EPS, and free cash flow cannot be quantified. The company reported $155.1 million of cash and effective disclosure controls as of June 30, 2026. The principal quantified concern is foreign-exchange exposure: a 10% adverse move could change net current assets by approximately $1.8 million and would have affected six-month net loss by approximately $4.8 million.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- $155.1M Cash Balance
- Cash and cash equivalents were $155.1 million as of June 30, 2026, held primarily for working capital purposes. The filing states the company does not believe short-term investments create material fair-value exposure to interest-rate changes.
- Effective Disclosure Controls
- Management concluded that disclosure controls and procedures were effective as of June 30, 2026, and reported no change during the six months ended June 30, 2026 that materially affected, or was reasonably likely to materially affect, internal control over financial reporting.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Foreign Exchange Translation Risk
- A hypothetical 10% adverse change in foreign exchange rates, primarily the euro, would reduce the translated net current assets of the German and Australian subsidiaries by approximately $1.8 million; those subsidiaries had $17.5 million of net current assets as of June 30, 2026.
- FX Could Affect Net Loss
- For the six months ended June 30, 2026, a 10% change in foreign-currency exchange rates would have affected net loss by approximately $4.8 million, primarily due to the euro. The company currently has no foreign-currency hedges or derivatives planned.
- Interest Income Sensitivity
- Cash of $155.1 million is exposed to changes in future investment income: decreases in interest rates would reduce investment income, while increases would raise it. The company states the investments are held for working capital and not trading or speculative purposes.
What they said about what is next.
The provided 10-Q text contains no quantitative revenue or EPS outlook. No change to prior guidance is disclosed; outlook appears deferred to the earnings release or call.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 13, 2026
- Immunic, Inc. reported a net loss of $32.6 million for Q1 2026, which reflects a 28% increase compared to a net loss of $25.5 million in Q1 2025. Operating expenses totaled $33.2 million, with significant growth in…
- 10-K · April 22, 2026
- This Form 10-K/A amends Part III (Items 10–14) of Immunic’s original 2025 Form 10-K to include board, executive compensation, ownership and auditor disclosures. Key governance changes disclosed include a nine-member…
- 10-K · February 26, 2026
- Immunic is a late-stage biotech focused on oral small-molecule therapies, led by vidofludimus calcium (IMU-838) in two Phase 3 ENSURE trials and earlier-stage programs IMU-856 and IMU-381. The company completed ENSURE…
- 10-Q · August 7, 2025
- Immunic reported a wider GAAP net loss in Q2 2025 of $(26,820) versus $(21,380) in Q2 2024, while reported diluted loss per share improved slightly to $(0.20) from $(0.21) due to a larger share count. Operating expenses…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing IMUX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever